$BHIC

BioScience Health Innovations, Inc.

CIK:0001784440|SEC Filings

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Details {2}
Revenues	$ 1,036,364	$ 1,757,463	$ 1,787,310	$ 2,984,533
Cost of goods sold	(376,881)	(682,985)	(642,231)	(1,013,910)
Gross Profit	659,483	1,074,478	1,145,079	1,970,623
Operating Expenses
General and administrative expenses	804,136	540,074	1,429,945	973,635
Consulting fees	73,229	76,700	162,923	112,486
Total Operating Expenses	877,365	616,774	1,592,868	1,086,121
Income (Loss) from Operations	(217,882)	457,704	(447,789)	884,502
Income tax expense	(32,129)	0	(32,129)	0
Net Income/Loss	$ (185,753)	$ 457,704	$ (415,660)	$ 884,502
Net income (loss) per common share - basic	$ (0.02)	$ 0.04	$ (0.04)	$ 0.08
Net income (loss) per common share - diluted	$ (0.02)	$ 0.04	$ (0.04)	$ 0.08
Weighted average common shares outstanding - basic	11,684,349	10,979,058	11,353,205	10,979,058
Weighted average common shares outstanding - diluted	11,684,349	11,399,058	11,353,205	11,399,058

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2026	Mar. 31, 2026	Jun. 30, 2025	Mar. 31, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Cash Flows From Operating Activities
Net Income (Loss)	$ (185,753)	$ (229,907)	$ 457,704	$ 426,798	$ (415,660)	$ 884,502	$ 642,090
Adjustments to reconcile net loss to net cash used in operating activities
Lease cost, net of repayments					26,244	0
Operating expenses paid with digital assets					4	0
Income tax receivable					(34,992)	0
Digital assets					(8,519)	0
Income tax payable					(79,030)	0
Deferred tax asset					2,069	0
Changes in operating assets and liabilities
Accounts receivable					2,358	(289,728)
Inventory					(456,820)	(190,200)
Deferred revenue					(134,041)	224,330
Accrued expenses					20,585	18,507
Accounts payable					3,441	8,410
Prepaid expenses					(19,620)	(42,502)
Net Cash Provided by (Used in) Operating Activities					(1,093,981)	613,319	172,178
Cash Flows From Investing Activities
Purchase of intangible assets					(26,958)	(46,064)
Net Cash Used in Investing Activities					(26,958)	(46,064)
Cash Flows From Financing Activities
Advances from related parties					748,120	1,391,635
Repayment of related party advances					(150,000)	(1,322,000)
Repayment of related party note payable					(200,000)	0
Proceeds from the sale of common stock					773,272	0
Net Cash Provided by Financing Activities					1,171,392	69,635
Net Increase in Cash					50,453	636,890
Cash at Beginning of Period		$ 661,925		$ 662,517	661,925	662,517	662,517
Cash at End of Period	$ 712,378		$ 1,299,407		712,378	1,299,407	$ 661,925
Supplemental Cash Flow Information
Cash paid for interest					0	0
Cash paid for income taxes					0	0
Non-Cash Investing and Financing Activities:
Conversion of related party advances to related party note payable					460,402	0
Purchase of inventory with digital assets					$ 4,015	$ 0

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current Assets
Cash and cash equivalents	$ 712,378	$ 661,925
Accounts receivable, net	396,899	399,257
Income tax receivable	34,992	0
Operating digital assets	4,500	0
Inventory	797,183	336,348
Prepaid expense	40,961	21,341
Overpayment to related parties	0	137,718
Deferred tax asset	0	2,069
Total current assets	1,986,913	1,558,658
Other Assets
Intangible assets	109,845	82,887
Deposits	4,400	4,400
Right-of-use asset	34,992	61,236
Total other assets	149,237	148,523
Total Assets	2,136,150	1,707,181
Current liabilities:
Accounts payable	9,715	6,274
Accrued expenses	28,542	7,957
Income tax payable	0	79,030
Deferred revenue	2,550	136,590
Note payable - related party	260,402	0
Total current liabilities	301,209	229,851
STOCKHOLDERS' EQUITY (DEFICIT)
Series A Convertible Preferred Stock, 1,000,000 designated, 140,000 shares issued and outstanding at June 30, 2026 and December 31, 2025	14	14
Common stock: $0.0001 par value, 250,000,000 shares authorized; 11,752,329 and 10,979,058 shares issued and outstanding at June 30, 2026 and December 31, 2025	1,176	1,098
Additional paid-in capital	1,948,404	1,175,211
Accumulated earnings (deficit)	(114,653)	301,007
Total stockholders' equity (deficit)	1,834,941	1,477,330
Total Liabilities and Stockholders' Equity (Deficit)	$ 2,136,150	$ 1,707,181